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Novelty and Impact: In two large prospective cohorts of US women, compared to those with no 
nevi on extremity, there is an increase in overall internal cancer risk among individuals with ≥ 1 nevi 
in a dose-dependent trend. To the best of our knowledge, this is the first study reporting higher nevus 
count is associated with an increased risk of internal cancer; further investigations are needed to 
evaluate nevus count as a phenotypic marker of cancer risk. 
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Abstract 
Elevated cutaneous nevus number has been linked to longer telomeres. Recently, a large 
systematic Mendelian randomization study identified a significant positive association between 
telomere length and risk of cancer. Here, we hypothesized that higher nevus count, as a phenotypic 
marker of longer telomere, may be associated with increased risk of internal cancer, and 
prospectively examined the association between nevus count and total as well as site-specific cancer 
risk among participants in the Nurses’ Health Study (NHS, 1986-2012) and the Nurses’ Health Study 
2 (NHS2, 1989-2013) using Cox proportional hazards models. During 3,900,264 person-years of 
follow-up, we documented a total of 23,004 internal cancer cases (15,484 in the NHS and 7,520 in 
the NHS2). Compared to participants who had no nevi, the multivariate hazard ratios of total cancer 
(excluding skin cancer) were 1.06 (95% confidence interval [CI], 1.03-1.09) for women with 1-5 
nevi, 1.08 (95% CI, 1.03-1.15) for those who had 6-14 nevi, and 1.19 (95% CI, 1.05-1.35) for those 
with 15 or more nevi (p trend < 0.0001). Moreover, because nevus count has been associated with 
risk of breast cancer previously, we conducted a secondary analysis by excluding breast cancer from 
the outcomes of interest. The results were very similar to those of our primary analysis. For 
individual cancer, most of the associations with nevus count were positive but not statistically 
significant. In conclusion, we identified the number of cutaneous nevi as a phenotypic marker 
associated with internal cancer risk, which may be explained by telomere biology.  
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Introduction 
Nevi, also referred to as moles, are benign clonal proliferations of melanocytes 1. Sun exposure 
may be involved in nevus formation, but variation in nevus count between individuals is primarily 
determined by genetic factors, as shown by family and twin studies 2-4.  
Elevated nevus number has been associated with longer telomeres 5, 6. And telomere length has 
been implicated in cancer development 7. Despite inconsistent results from observational studies 8-12, 
a recent systematic Mendelian randomization study reported a positive association between telomere 
length and risk of cancer 13. Their findings are generally consistent with those from previous 
prospective observational studies, most of which found weak positive association or null association 
between telomere length and total as well as site-specific cancer risk 5, 11, 14-26. Moreover, the results 
are similar to those reported by several other Mendelian randomization studies on the association of 
telomere length with risk of lung cancer, melanoma, glioma, and chronic lymphocytic leukemia 27-30.  
Having a large number of nevi on sun-exposed body sites is a well-known risk factor for 
malignant melanoma 31, 32. However, limited evidence is available for the association between 
number of nevi and risk of internal cancer. In the current study, we hypothesized that higher nevus 
count, as a phenotypic marker of longer telomere, may be associated with increased internal cancer 
risk, and prospectively investigated this association in two large cohorts of US women. 
 
Methods 
Study Population, Inclusion, and Exclusion 
Our study population consisted of participants from two ongoing cohort studies: the Nurses’ 
Health Study (NHS) and the Nurses’ Health Study 2 (NHS2). The NHS is a prospective cohort study 
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established in 1976 with 121,700 female U.S registered nurses who were then 30-55 years old. All of 
them completed and returned a mailed self-administered questionnaire about their medical histories 
and lifestyle at baseline. The NHS2 was established in 1989, when 116,671 female registered nurses 
aged 25–42 and residing in the United States at the time of enrollment responded to an initial 
questionnaire on their medical histories and baseline health-related exposures. In both cohorts, 
information regarding medical history, lifestyle, and disease diagnoses was updated every 2 years 
with a follow-up rate of 90%.  
In the present analyses, the baselines in the NHS and NHS2 were 1986 and 1989, respectively, 
when participants reported self-counted number of cutaneous nevi. We excluded participants 
diagnosed with cancer before baseline. Participants who did not report number of cutaneous nevi 
were excluded, as were those reporting non-white ancestry. In total, 72,726 women from the NHS 
and 103,766 from the NHS2 were included. The study was approved by the Institutional Review 
Board of Brigham and Women’s hospital and the Harvard T.H. Chan School of Public Health, and 
those of participating registries as required.  
 
Measurements of nevus count and other covariates 
In the NHS, in 1986, participants were asked to provide information on melanocytic nevus count 
(larger than 3 mm in diameter) from shoulder to wrist on left arm by choosing from the following 
categories: none, 1-2, 3-5, 6-9, 10-14, 15-20, and 21+. In the baseline questionnaire in 1989, the 
NHS2 participants reported numbers of cutaneous nevi, without specification of size, on lower legs 
(knees to ankles, both legs) using the same categories. 
Data on body mass index (BMI), smoking status, physical activity, menopausal status, use of 
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postmenopausal hormones, and disease history (including heart disease, stroke, type 2 diabetes, 
squamous cell carcinoma, and basal cell carcinoma) was first collected at baseline and then updated 
biennially in subsequent questionnaires for both cohorts. Information on alcohol consumption was 
first asked in 1986 and 1991 in the NHS and NHS2, respectively, and then updated every four years. 
In 1990s, participants were asked about their location of residence (US states) at birth, age 15, and 
age 30. The 50 US states were categorized into low, medium, and high ultraviolet (UV) index groups 
33 and incorporated into the multivariable-adjusted models. 
 
Ascertainment of cancer cases 
 Participants in the NHS and NHS2 reported diagnosis of cancers every two years. With their 
permission, medical records were then obtained and reviewed by physicians to confirm their 
self-reported diagnosis. Eligible cases consisted of women with incident cancers (excluding 
melanoma and non-melanoma skin cancers) diagnosed any time after baseline up to the 2012 
follow-up cycle in the NHS and 2013 follow-up cycle in the NHS2. Only pathologically confirmed 
invasive cases were included. In total, 23,004 internal cancer cases were documented (15,484 in the 
NHS and 7,520 in the NHS2).  
 
Statistical analysis 
 We used age-adjusted and multivariable-adjusted Cox proportional hazards models stratified by 
follow-up cycles and age to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) of the 
association between nevus count and internal cancer risk. Person-time was calculated for each 
participant from the date of baseline questionnaire return to the date of the first report of cancer 
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diagnosis, death, or the end of follow-up, whichever came first. We grouped women into four 
categories based on their self-reported nevus count (none, 1-5, 6-14, and 15+) and created a 
continuous variable (0, 3, 10, and 15) to represent the four exposure categories for the linear trend 
test. In the multivariate analysis, we simultaneously controlled for age, smoking status, alcohol 
intake, BMI, physical activity, UV index, menopausal status/postmenopausal hormone use, and 
history of heart disease, stroke, type 2 diabetes, squamous cell carcinoma, and basal cell carcinoma. 
We used the most updated information for time-varying variables prior to each follow-up interval to 
take into account potential changes over follow-up. Missing data during any follow-up interval were 
coded as a missing indicator category for categorical variables and with carried-forward values for 
continuous variables. Multiplicative interactions between nevus count and other covariates were 
tested using the likelihood ratio test comparing a “main effect only” model vs. a model with product 
term. All covariates in the multivariable-adjusted models were considered individually and 
sequentially tested for interaction. We tested the heterogeneity of the results between the two cohorts 
using the Q statistic and conducted a fixed-effect inverse variance-weighted meta-analysis if there 
was no significant difference 34, 35. All statistical analyses were performed using SAS software 
(version 9.4 for UNIX; SAS Institute, Cary, North Carolina). We considered two-sided P values less 
than 0.05 to be statistically significant. 
 
Data Availability 
Further information including the procedures to obtain and access data from the Nurses’ Health 
Studies is described at https://www.nurseshealthstudy.org/researchers (contact email: 
nhsaccess@channing.harvard.edu). 
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Results 
 The baseline age-standardized characteristics of participants by categories of nevus count are 
listed in Table 1. Compared to participants who reported having no nevi on their arms/legs, women 
in higher nevus count categories were less likely to be current smokers, and more likely to have 
personal history of basal cell carcinoma (in both cohorts), squamous cell carcinoma and type 2 
diabetes (in NHS). Other characteristics were similar among groups having different numbers of 
cutaneous nevi.  
 During 3,900,264 person-years of follow-up, we documented a total of 23,004 internal cancer 
cases (15,484 in the NHS and 7,520 in the NHS2). In both cohorts, higher numbers of cutaneous nevi 
were associated with increased risk of cancer, though the multivariate HRs are slightly higher in the 
NHS compared to those in the NHS2 for women with 6-14 and 15+ nevi (Table 2). Because we did 
not detect significant heterogeneity between the results of the NHS and NHS2 (p for heterogeneity in 
trend test = 0.14 for multivariable-adjusted model), we combined the estimates using fixed-effect 
inverse variance-weighted meta-analysis. Compared to participants who had no nevi, the multivariate 
HRs were 1.06 (95% CI, 1.03-1.09) for women with 1-5 nevi, 1.08 (95% CI, 1.03-1.15) for those 
who had 6-14 nevi, and 1.19 (95% CI, 1.05-1.35) for those with 15 or more nevi (P for trend < 
0.0001). Additionally, we did not find significant interactions between the number of nevi and other 
covariates in the multivariable-adjusted model after adjusting for multiple comparisons (p-values for 
interaction > 0.05 for all covariates). 
 Nevus count has been associated with risk of breast cancer previously 36. Thus, we conducted a 
secondary analysis by excluding breast cancer from the outcomes of interest. The results 
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(Supplementary Table 1) were very similar to those of our primary analysis using all internal cancer 
sites. Moreover, we assessed the associations between nevus count and risk of developing 
site-specific cancers (Supplementary Table 2). We combined the results of trend tests for total and 
site-specific cancer of the two cohorts, and presented the HRs and 95% CIs associated with per 5 
count increase in nevus number in Figure 1. For individual cancer sites, results of bladder cancer, 
lymphoma, and breast cancer reached borderline significance, associations with nevus count for the 
remaining cancer sites were positive but not statistically significant. 
 
Discussion 
 In this analysis of two large prospective cohort studies, the number of cutaneous nevi was 
positively associated with incidence of total internal cancer with a significant dose-response 
relationship. After adjusting for potential confounding factors, there was a 19% higher risk of overall 
cancer among participants with ≥15 nevi on their limbs as compared to those without any nevi. 
Importantly, the association remained significant in the secondary analysis, indicating that the 
observed significant association was not solely driven by previously reported association between 
nevus count and breast cancer. The association with nevus count was nonsignificant for most of the 
individual cancer sites, which may be due to a lack of power. These findings suggest that nevus 
count may be etiologically linked to cancer development. 
 One potential mechanism for this association is telomere length which has been linked to both 
nevus count and risk of cancer. Telomeres are long hexameric (TTAGGG)n repeats at the ends of 
linear eukaryotic chromosomes that are shortened by each round of DNA replication 37. They serve 
to track the number of divisions a cell has undergone and reflect the future replication potential of a 
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cell 7. Efforts have been made to study relationships between telomere length and cancer risk. 
However, the direction and magnitude of the associations found are inconsistent across observational 
studies, e.g., retrospective studies tend to report increased cancer risk among individuals with shorter 
telomeres 9, 10, 38, whereas more prospective studies find weak or null associations of telomere length 
with overall and site-specific cancer 5, 8-10, 16, 22, 23, 26, 39-42. Such inconsistency may reflect reverse 
causation bias in the retrospective design or variation in controlling confounding effects due to 
shared environmental factors. To rule out the influences of these methodological issues, Haycock et 
al. recently conducted a systematic Mendelian randomization study with more than 1,200,000 
participants and found that increased telomere length is associated with increased risk of cancers 13. 
This positive association is supported by known biology. Telomere length may regulate senescence 
process. When telomeres shorten to a critical length, the cells may enter senescence, an important 
tumor-suppressive mechanism 7. Cells with longer telomeres have higher proliferative potential, 
leading to acquiring more somatic mutations 43. Previous studies found that telomeres appear to be 
longer among people with more and larger nevi 5, 6. Consistent with those findings, we report 
increased cancer risk among women with more cutaneous nevi.  
 Alternatively, nevus count and cancer may be connected through growth factors, as they both 
positively related to adult height. Data suggested that melanocytic nevi grow more rapidly during 
growth hormone (GH) therapy 44. Growth hormone exerts many of its functions through insulin-like 
growth factor (IGF)-1, which has numerous roles, including accelerating cell proliferation and 
inhibiting apoptosis 45, 46. The GH-IGF-1 axis has been demonstrated to play a role in the 
development of most common cancers among Western populations 47. 
 Our study has several strengths. First, this is a prospective cohort study with large sample size, 
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long follow-up, and updated assessment of cancer diagnosis every two years. Second, we were able 
to control for a number of potential confounders based on detailed cohort follow-up information, and 
this allowed us to determine that the association between nevus count and cancer risk was 
independent of the confounders being considered. Third, besides primary analysis, we also tested the 
association of nevus count with risk of total internal cancer (excluding breast cancer) and individual 
cancer to better illustrate the observed positive association.  
 We also acknowledge several limitations. One is that nevus count in our cohorts was 
self-reported. However, previous studies have evaluated the validity of self-reported information on 
nevus counts, and the majority found substantial agreement between nevus self-counts and 
dermatologist counts 48, 49. In one study, the Spearman’s correlation coefficient was 0.91 between the 
two measurements 50. In our cohorts, the ordinal variable of nevus count is a highly significant 
predictor of melanoma risk 51. Genome-wide association studies of nevi number using our genetic 
datasets revealed biologically plausible susceptibility loci for nevus count and melanoma risk, and 
the same loci were replicated by other independent studies 52-54. In addition, we do not have 
information on type or size of nevi, thus could not evaluate whether the association of interest is 
modified by these histopathological factors. The second limitation was that we collected information 
on nevus count on the left arm in the NHS, while on both legs in the NHS2. Despite such difference, 
conclusion regarding association between nevus count and cancer risk was consistent based on 
cohort-specific results. And examining the limbs was suggested previously to be a practical and 
suitable tool for predicting whole body nevus count 55-57. Thirdly, average number of nevi varies 
among different age groups. Studies found nevus count typically reaches its maximum between ages 
30 and 50, with a slight decrease after age 50 58. Considering participants of the NHS (age range 
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40-65 when nevus count was asked) on average are older than those of the NHS2 (age range 25-42 
when nevus count was asked), natural regression of nevus may influence results in the NHS. 
Furthermore, our cohorts consist primarily of white, educated US women, and thus results may not 
be generalizable. However, such homogeneity in a study population would minimize confounding by 
socioeconomic status and differential access to healthcare and assure a high quality of returned data.  
 In conclusion, we identified the number of cutaneous nevi as a novel phenotypic marker 
associated with internal cancer risk. Telomere length and growth factors may contribute to this 
association. Further studies are needed to better assess the relationships between nevus count and 
individual cancer sites and to reveal the underlying mechanisms. 
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Table 1. Age-adjusted baseline characteristics according to categories of nevus count in the NHS and NHS2 
 
 NHS  
(number of nevi on left arm from shoulder to wrist) 
NHS2 
(number of nevi on both lower legs from knees to 
ankles) 
 None 
(n=46,136) 
1-5 
(n=23,304) 
6-14 
(n=2,643) 
>=15 
(n=643) 
None 
(n=51,756) 
1-5 
(n=30,216) 
6-14 
(n=12,295) 
>=15 
(n=9,499) 
Age (year) a, mean (SD) 52.7 (7.2) 52.0 (7.1) 51.9 (7.1) 52.0 (7.1) 34.3 (4.7) 34.4 (4.6) 34.3 (4.7) 34.3 (4.6) 
Body mass index (kg/m2), mean (SD) 25.1 (4.7) 25.6 (5.0) 26.5 (5.5) 26.9 (5.7) 24.3 (5.2) 24.1 (5.1) 23.8 (4.8) 23.5 (4.5) 
Height (inch), mean (SD) 64.4 (3.1) 64.5 (3.2) 64.7 (3.0) 64.9 (2.5) 64.9 (2.6) 64.9 (2.6) 65.0 (2.6) 65.2 (2.6) 
Current smoking, % 22.3 20.6 20.2 19.4 14.1 13.8 11.8 10.1 
Alcohol intake (g/d), mean (SD) 6.3 (11.0) 6.0 (10.4) 5.7 (9.8) 5.0 (8.5) 3.0 (5.8) 3.0 (5.5) 3.0 (5.7) 3.1 (6.2) 
Physical activity (metabolic-equivalents 
hours/wk), mean (SD) 14.1 (20.8) 13.9 (20.7) 13.5 (19.3) 14.8 (24.6) 25.3 (37.3) 24.5 (35.6) 24.4 (36.0) 24.8 (36.2) 
Menopausal status/PMH b status         
- Premenopausal, % 43.2. 43.3 44.4 44.9 97.2 96.8 97.1 97.1 
- PMH never use, % 26.2 25.5 25.1 21.9 0.2 0.2 0.2 0.1 
- PMH current use, % 14.0 14.5 14.7 16.0 0.2 0.2 0.2 0.2 
- PMH past use, % 12.4 12.9 11.9 14.3 1.8 2.1 2.1 2.0 
UV index at birth, age 15, and age 
30 >=7, % 5.5 5.9 4.5 5.5 9.7 11.5 10.7 10.7 
Personal history of BCC b 4.4 5.6 7.3 8.0 0.3 0.4 0.4 0.5 
Personal history of SCC b 0.3 0.3 0.4 0.5 0.0 0.0 0.0 0.0 
Personal history of T2D b 3.9 4.5 6.2 5.7 0.2 0.2 0.2 0.1 
NOTE: Values are means (SD) or percentages and are standardized to the age distribution of the study populations. Values of multi-level categorical 
variables may not sum to 100% due to rounding or missingness. 
a Value is not age-adjusted; 
b Abbreviation: PMH – postmenopausal hormone use; BCC – basal cell carcinoma; SCC – squamous cell carcinoma; T2D – type 2 diabetes. 
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Table 2. HRs and 95% CIs for the association between nevus count and total internal cancer risk 
 
 Levels of nevus count P for trend 
 None 1-5 6-14 15 and up  
NHS      
  Person-years 996,663 503,996 56,378 13,273 . 
  No. of cases 9,672 5,053 596 163 . 
  Age-adjusted HR 1 1.06 (1.03, 1.10) 1.12 (1.03, 1.22) 1.33 (1.14, 1.56) <.0001 
  Multivariate HR a 1 1.05 (1.02, 1.09) 1.10 (1.01, 1.19) 1.30 (1.11, 1.52) <.0001 
 
NHS2      
  Person-years 1,164,586 677,135 275,691 212,542  
  No. of cases 3,578 2,269 923 750  
  Age-adjusted HR 1 1.09 (1.03, 1.15) 1.09 (1.01, 1.17) 1.16 (1.07, 1.25) 0.0001 
  Multivariate HR a 1 1.08 (1.03, 1.14) 1.07 (1.00, 1.16) 1.14 (1.05, 1.23) 0.0011 
      
Meta-analysis b      
  Person-years 2,161,249 1,181,131 332,069 225,815  
  No. of cases 13,250 7,322 1,519 913  
  Age-adjusted HR 1 1.07 (1.04, 1.10) 1.10 (1.04, 1.17) 1.22 (1.07, 1.39) <.0001 
  Multivariate HR 1 1.06 (1.03, 1.09) 1.08 (1.03, 1.15) 1.19 (1.05, 1.35) <.0001 
 
a Multivariate models adjusted for age, smoking status (never, past, current 1-14,15-24, or 25+ cigarettes/day), alcohol intake (no, <5.0, 5.0-9.9, 10.0-19.9, 
or 20.0+ g/day), body mass index (<25.0, 25.0-29.9, 30.0-34.9, or 35.0+ kg/m2), physical activity (<3.0, 3.0-8.9, 9.0-17.9, 18.0-26.9 or 27.0+ metabolic 
equivalent hours/wk), history of heart disease (yes or no), history of stroke (yes or no), history of type 2 diabetes (yes or no), history of squamous cell 
carcinoma (yes or no), history of basal cell carcinoma (yes or no), menopausal status/postmenopausal hormones use (premenopausal, PMH never, PMH past, 
or PMH current), and states lived at birth, age 15, and age 30 (UV index <=5, =6, or >=7); 
b No significant difference were found between results of the NHS and the NHS2, p-value for heterogeneity is greater than 0.05. 
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Figure Legend 
 
Figure 1. Multivariable-adjusted HRs and 95% CIs of per 5 count increase in nevus count for incident cancer at 15 specific sites, total internal 
cancer, and total internal cancer excluding breast cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1. HRs and 95% CIs for the association between nevus count and total internal cancer (excluding breast cancer) risk 
 
 Levels of nevus count P for trend 
 None 1-5 6-14 15 and up  
NHS      
  Person-years 937,758 472,459 52,622 12,220  
  No. of cases 6,020 3,114 351 97  
  Age-adjusted HR 1 1.06 (1.02, 1.11) 1.09 (0.98, 1.21) 1.31 (1.07, 1.60) 0.0004 
  Multivariate HR a 1 1.06 (1.02, 1.11) 1.07 (0.96, 1.19) 1.28 (1.05, 1.57) 0.0018 
 
NHS2      
  Person-years 1,136,405 658,967 268,641 206,560  
  No. of cases 2,049 1,310 543 438  
  Age-adjusted HR 1 1.10 (1.03, 1.18) 1.12 (1.01, 1.23) 1.18 (1.07, 1.31) 0.0005 
  Multivariate HR a 1 1.10 (1.02, 1.18) 1.11 (1.01, 1.22) 1.18 (1.06, 1.31) 0.0006 
      
Meta-analysis b      
  Person-years 2,074,163 1,131,426 321,263 218,780  
  No. of cases 8,069 4,424 894 535  
  Age-adjusted HR 1 1.07 (1.04, 1.12) 1.10 (1.03, 1.19) 1.21 (1.10, 1.33) <.0001 
  Multivariate HR 1 1.07 (1.03, 1.11) 1.09 (1.02, 1.17) 1.20 (1.09, 1.32) <.0001 
 
a Multivariate models adjusted for age, smoking status (never, past, current 1-14,15-24, or 25+ cigarettes/day), alcohol intake (no, <5.0, 5.0-9.9, 10.0-19.9, 
or 20.0+ g/day), body mass index (<25.0, 25.0-29.9, 30.0-34.9, or 35.0+ kg/m2), physical activity (<3.0, 3.0-8.9, 9.0-17.9, 18.0-26.9 or 27.0+ metabolic 
equivalent hours/wk), history of heart disease (yes or no), history of stroke (yes or no), history of type 2 diabetes (yes or no), history of squamous cell 
carcinoma (yes or no), history of basal cell carcinoma (yes or no), menopausal status/postmenopausal hormones use (premenopausal, PMH never, PMH past, 
or PMH current), and states lived at birth, age 15, and age 30 (UV index <=5, =6, or >=7); 
b No significant difference were found between results of the NHS and the NHS2, p-value for heterogeneity is greater than 0.05. 
 
 
Supplementary Table 2. Risks of subsequent primary cancers at different sites a according to levels of nevus count in the NHS and NHS2 
 
  
NHS NHS2 
Levels of nevus count P for 
trend 
Levels of nevus count P for 
trend None 1-5 6-14 15 and up None 1-4 5-14 15 and up 
Breast cancer 1 
Person-years 1014997 517422 58789 13772 . 1171323 682624 278852 216265 . 
No. of cases 3652 1939 245 66 . 1529 959 380 312 . 
Age-adjusted HR 1 
1.06  
(1.00, 1.12) 
1.17  
(1.03, 1.33) 
1.38  
(1.08, 1.76) 
0.0003 1 
1.07  
(0.99, 1.16) 
1.04  
(0.93, 1.17) 
1.12  
(0.99, 1.26) 
0.09 
Multivariate HR b 1 
1.03  
(0.97, 1.09) 
1.11  
(0.97, 1.27) 
1.35  
(1.05, 1.72) 
0.0089 1 
1.05  
(0.97, 1.14) 
0.99  
(0.88, 1.11) 
1.03  
(0.91, 1.17) 
0.84 
Lung cancer 
Person-years 1017783 518912 58969 13816 . 1172668 683432 279169 216538 . 
No. of cases 1184 531 68 15 . 117 53 25 18 . 
Age-adjusted HR 1 
0.92  
(0.83, 1.02) 
1.07  
(0.84, 1.37) 
1.01  
(0.61, 1.69) 
0.77 1 
0.78  
(0.56, 1.07) 
0.91  
(0.59, 1.41) 
0.84  
(0.51, 1.38) 
0.49 
Multivariate HR 1 
0.96  
(0.86, 1.06) 
1.15  
(0.90, 1.47) 
1.10  
(0.66, 1.84) 
0.60 1 
0.77  
(0.55, 1.06) 
0.94  
(0.61, 1.46) 
0.93  
(0.56, 1.54) 
0.77 
Colorectal cancer 
Person-years 1017666 518818 58981 13822 . 1172607 683389 279153 216518 . 
No. of cases 933 504 48 14 . 159 103 44 32 . 
Age-adjusted HR 1 
1.12  
(1.01, 1.25) 
0.95  
(0.71, 1.27) 
1.17  
(0.69, 1.98) 
0.34 1 
1.13  
(0.88, 1.44) 
1.13  
(0.81, 1.58) 
1.09  
(0.74, 1.59) 
0.52 
Multivariate HR 1 
1.12  
(1.00, 1.25) 
0.93  
(0.70, 1.25) 
1.14  
(0.67, 1.94) 
0.42 1 
1.12  
(0.87, 1.43) 
1.13  
(0.80, 1.58) 
1.07  
(0.73, 1.57) 
0.56 
Endometrial  
cancer 2 
Person-years 1017803 518886 58976 13823 . 1172531 683349 279150 216513 . 
No. of cases 737 395 41 12 . 228 153 44 38 . 
Age-adjusted HR 1 
1.07  
(0.94, 1.21) 
0.98  
(0.71, 1.34) 
1.26  
(0.71, 2.23) 
0.46 1 
1.14  
(0.93, 1.40) 
0.81  
(0.59, 1.12) 
0.90  
(0.64, 1.27) 
0.24 
Multivariate HR 1 
1.02  
(0.90, 1.15) 
0.86  
(0.63, 1.18) 
1.07  
(0.60, 1.91) 
0.70 1 
1.14  
(0.93, 1.41) 
0.84  
(0.61, 1.16) 
0.95  
(0.67, 1.35) 
0.41 
Ovarian cancer 2 Person-years 1018149 519062 59000 13824 . 1172608 683380 279162 216523 . 
No. of cases 421 222 23 9 . 144 94 34 27 . 
Age-adjusted HR 1 
1.07  
(0.91, 1.26) 
0.96  
(0.62, 1.46) 
1.58 
(0.81, 3.06) 
0.37 1 
1.11  
(0.85, 1.44) 
0.99  
(0.68, 1.44) 
1.03  
(0.68, 1.55) 
0.98 
Multivariate HR 1 
1.07  
(0.91, 1.26) 
0.95  
(0.62, 1.45) 
1.53  
(0.78, 2.97) 
0.43 1 
1.11  
(0.85, 1.44) 
0.99  
(0.68, 1.43) 
1.00  
(0.66, 1.51) 
0.93 
Bladder cancer 
Person-years 1018287 519113 59003 13830 . 1172721 683464 279187 216544 . 
No. of cases 229 132 14 2 . 18 13 7 8 . 
Age-adjusted HR 1 
1.15  
(0.92, 1.42) 
1.09  
(0.64, 1.88) 
0.63  
(0.16, 2.54) 
0.68 1 
1.25  
(0.61, 2.56) 
1.61  
(0.67, 3.86) 
2.44  
(1.06, 5.65) 
0.03 
Multivariate HR 1 
1.16  
(0.93, 1.44) 
1.13  
(0.66, 1.95) 
0.69  
(0.17, 2.80) 
0.54 1 
1.33  
(0.64, 2.74) 
1.78  
(0.73, 4.32) 
2.82  
(1.21, 6.60) 
0.01 
Pancreas cancer 
Person-years 1018374 519196 59007 13828 . 1172722 683462 279187 216547 . 
No. of cases 259 124 19 7 . 28 15 6 5 . 
Age-adjusted HR 1 
0.98  
(0.79, 1.22) 
1.37  
(0.86, 2.19) 
2.27  
(1.07, 4.83) 
0.06 1 
0.93  
(0.49, 1.74) 
0.91  
(0.37, 2.19) 
0.98  
(0.38, 2.54) 
0.89 
Multivariate HR 1 
0.99  
(0.79, 1.22) 
1.35  
(0.84, 2.16) 
2.20  
(1.03, 4.70) 
0.07 1 
0.93  
(0.49, 1.75) 
0.96  
(0.39, 2.33) 
1.05  
(0.40, 2.75) 
0.97 
Kidney cancer 
Person-years 1018348 519163 59009 13826 . 1172680 683434 279180 216531 . 
No. of cases 172 104 11 3 . 63 38 13 14 . 
Age-adjusted HR 1 
1.23  
(0.96, 1.57) 
1.12  
(0.61, 2.07) 
1.34  
(0.43, 4.20) 
0.24 1 
1.02  
(0.68, 1.53) 
0.85  
(0.47, 1.54) 
1.20  
(0.67, 2.15) 
0.83 
Multivariate HR 1 
1.19  
(0.93, 1.52) 
1.03  
(0.56, 1.90) 
1.18  
(0.37, 3.73) 
0.46 1 
1.00  
(0.66, 1.49) 
0.85  
(0.46, 1.54) 
1.24  
(0.69, 2.23) 
0.77 
Melanoma 3 
Person-years 1018151 518946 58937 13820 . 1172520 683308 279078 216427 . 
No. of cases 394 327 78 14 . 204 165 110 132 . 
Age-adjusted HR 1 
1.64  
(1.41, 1.90) 
3.47  
(2.72, 4.44) 
2.74  
(1.60, 4.68) 
<.0001 1 
1.38  
(1.13, 1.70) 
2.28  
(1.80, 2.87) 
3.48  
(2.80, 4.34) 
<.0001 
Multivariate HR 1 
1.53  
(1.32, 1.78) 
3.02  
(2.35, 3.87) 
2.50  
(1.46, 4.28) 
<.0001 1 
1.35  
(1.10, 1.66) 
2.18  
(1.72, 2.75) 
3.10  
(2.48, 3.87) 
<.0001 
Stomach cancer 
Person-years 1018449 519227 59010 13831 . 1172736 683472 279189 216550 . 
No. of cases 72 33 7 2 . 7 3 2 2 . 
Age-adjusted HR 1 
0.97  
(0.64, 1.46) 
1.87  
(0.86, 4.08) 
2.39  
(0.58, 9.82) 
0.11 1 
0.71  
(0.18, 2.74) 
1.15  
(0.24, 5.55) 
1.53  
(0.32, 7.41) 
0.57 
Multivariate HR 1 
0.92  
(0.61, 1.40) 
1.76  
(0.80, 3.86) 
1.92  
(0.45, 8.11) 
0.21 1 
0.73  
(0.18, 2.91) 
1.36  
(0.27, 6.80) 
1.58  
(0.31, 8.00) 
0.50 
Brain cancer 
Person-years 1018439 519222 59011 13830 . 1172713 683460 279182 216546 . 
No. of cases 108 49 8 2 . 37 21 14 9 . 
Age-adjusted HR 1 
0.94  
(0.67, 1.31) 
1.34  
(0.65, 2.75) 
1.42  
(0.35, 5.80) 
0.54 1 
0.97  
(0.57, 1.65) 
1.54  
(0.83, 2.86) 
1.32  
(0.64, 2.75) 
0.18 
Multivariate HR 1 
0.92  
(0.65, 1.29) 
1.28  
(0.62, 2.64) 
1.27  
(0.31, 5.20) 
0.68 1 
0.96  
(0.56, 1.65) 
1.51  
(0.81, 2.80) 
1.25  
(0.60, 2.60) 
0.25 
Non-Hodgkin 
lymphoma 
Person-years 1017995 518961 58990 13828 . 1172618 683400 279156 216520 . 
No. of cases 594 332 32 8 . 134 80 38 36 . 
Age-adjusted HR 1 
1.13  
(0.99, 1.29) 
0.99  
(0.69, 1.42) 
1.07  
(0.53, 2.15) 
0.41 1 
1.01  
(0.77, 1.33) 
1.20  
(0.84, 1.73) 
1.44  
(1.00, 2.08) 
0.04 
Multivariate HR 1 
1.12  
(0.98, 1.28) 
0.98  
(0.69, 1.41) 
1.04  
(0.52, 2.09) 
0.49 1 
1.00  
(0.76, 1.33) 
1.18  
(0.82, 1.70) 
1.41  
(0.97, 2.04) 
0.06 
Leukemia 
Person-years 1018429 519217 59011 13832 . 1172711 683457 279186 216547 . 
No. of cases 108 72 8 2 . 33 21 7 8 . 
Age-adjusted HR 1 
1.39  
(1.03, 1.87) 
1.38  
(0.67, 2.83) 
1.34  
(0.33, 5.43) 
0.10 1 
1.07  
(0.62, 1.85) 
0.90  
(0.40, 2.04) 
1.35  
(0.62, 2.92) 
0.65 
Multivariate HR 1 
1.37  
(1.02, 1.86) 
1.30  
(0.63, 2.68) 
1.20  
(0.29, 4.92) 
0.16 1 
1.04  
(0.60, 1.80) 
0.85  
(0.38, 1.94) 
1.38  
(0.63, 3.02) 
0.66 
Multiple 
Myeloma 
Person-years 1018393 519213 59009 13832 . 1172726 683469 279184 216548 . 
No. of cases 131 51 8 0 . 17 7 6 7 . 
Age-adjusted HR 1 
0.82  
(0.59, 1.14) 
1.16  
(0.57, 2.38) 
NA c 0.38 1 
0.67  
(0.28, 1.64) 
1.52  
(0.59, 3.87) 
2.35  
(0.97, 5.69) 
0.04 
Multivariate HR 1 
0.81  
(0.58, 1.12) 
1.13  
(0.55, 2.33) 
NA c 0.34 1 
0.64  
(0.26, 1.58) 
1.50  
(0.58, 3.85) 
2.17  
(0.88, 5.38) 
0.06 
Oral cancer 
Person-years 1018428 519217 59013 13831 . 1172729 683460 279183 216546 . 
No. of cases 70 33 2 1 . 19 13 7 7 . 
Age-adjusted HR 1 0.92  0.48  1.11  0.42 1 1.16  1.40  2.13  0.09 
(0.61, 1.40) (0.12, 1.98) (0.15, 8.04) (0.57, 2.35) (0.58, 3.37) (0.89, 5.08) 
Multivariate HR 1 
0.93  
(0.61, 1.41) 
0.51  
(0.12, 2.08) 
1.27  
(0.17, 9.28) 
0.49 1 
1.11  
(0.55, 2.28) 
1.44  
(0.60, 3.50) 
2.23  
(0.93, 5.34) 
0.07 
Other  
cancers 
Person-years 1017856 518878 58968 13821 . 1171719 682784 278910 216325 . 
No. of cases 1002 532 62 20 . 1045 696 296 227 . 
Age-adjusted HR 1 
1.07  
(0.96, 1.19) 
1.10  
(0.85, 1.43) 
1.54  
(0.99, 2.41) 
0.05 1 
1.15  
(1.04, 1.26) 
1.19  
(1.05, 1.36) 
1.19  
(1.03, 1.37) 
0.003 
Multivariate HR 1 
1.07  
(0.97, 1.19) 
1.10  
(0.85, 1.42) 
1.52  
(0.97, 2.37) 
0.05 1 
1.14  
(1.04, 1.26) 
1.18  
(1.03, 1.34) 
1.16  
(1.01, 1.34) 
0.01 
a Cancer sites that have more than 100 diagnosed cases in either cohort were included in the single site analyses. Cancer sites with smaller numbers of 
cases were grouped as other cancers; 
b Multivariate models adjusted for age, smoking status (never, past, current 1-14,15-24, or 25+ cigarettes/day), alcohol intake (no, <5.0, 5.0-9.9, 10.0-19.9, 
or 20.0+ g/day), body mass index (<25.0, 25.0-29.9, 30.0-34.9, or 35.0+ kg/m2), physical activity (<3.0, 3.0-8.9, 9.0-17.9, 18.0-26.9 or 27.0+ metabolic 
equivalent hours/wk), history of heart disease (yes or no), history of stroke (yes or no), history of type 2 diabetes (yes or no), history of squamous cell 
carcinoma (yes or no), history of basal cell carcinoma (yes or no), menopausal status/postmenopausal hormones use (premenopausal, PMH never, PMH past, 
or PMH current), and states lived at birth, age 15, and age 30 (UV index <=5, =6, or >=7); 
c Estimates are not available because the number of cases is zero in those exposure categories; 
1 For breast cancer, we additionally included in the multivariate model duration of hormone replacement therapy use (pre-menopause, dubious menopause, 
post menopause age < 48 and never user, post menopause age < 48 and past user, post menopause age < 48 and current user < 5 y, post menopause age < 48 
and current user >= 5 y, 48 < post menopause age < 52 and never user, 48 < post menopause age < 52 and past user, 48 < post menopause age < 52 and 
current user < 5 y, 48 < post menopause age < 52 and current user >= 5 y, post menopause age >= 52 and never user, post menopause age >= 52 and past 
user, post menopause age >= 52 and current user < 5 y, post menopause age >= 52 and current user >=5 y), duration of menopause (continuous variable), 
family history of breast cancer (yes or no), history of benign breast disease (yes or no), height (< 160.02 cm, 160.02–162.56 cm, 162.56–167.64 cm, >= 
167.64 cm), weight change from age at 18 (loss > 4 kg, stable, gain 4–10 kg, gain 10–20 kg, gain 20–40 kg, gain > 40 kg), parity and age at first birth 
(nulliparous, parity 1–2 and age at first birth < 25, parity 1–2 and 25 < age at first birth < 30, parity 1–2 and age at first birth > 30, parity 3–4 and age at first 
birth < 25, parity 3–4 and 25 < age at first birth < 30, parity 3–4 and age at first birth > 30, parity >=5 and age at first birth < 25, parity >=5 and 25 < age at 
first birth < 30), and age at menarche (<=12 y, 13 y, >=14 y); 
2 For ovarian cancer and endometrial cancer, the multivariate model additionally included duration of hormone replacement therapy use, parity and age at 
first birth, and age at menarche, categorized as previously; 
3 For melanoma, the multivariate model additionally included childhood reaction to sun (some redness or none, burn, painful burn or blisters), number of 
severe sunburns (none, 1–2, 3–5, 6–9, >=10), hair color (black, dark brown, light brown, blonde, red), family history of melanoma (yes or no), average time 
spent in sun light in summer at different age intervals (0-2hr, 2-6hr, 6-10hr, >10hr), and cumulative UV flux (quintiles). 

